Amneal Pharmaceuticals, Inc.
AMRX
$1.31
$0.043.15%
Weiss Ratings | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | D | |||
Rating Factors | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Weak | |||
Solvency Index | Good | |||
Total Return Index | Very Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.17 | |||
Price History | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -8.39% | |||
30-Day Total Return | -46.96% | |||
60-Day Total Return | -34.17% | |||
90-Day Total Return | -41.26% | |||
Year to Date Total Return | -37.91% | |||
1-Year Total Return | -68.96% | |||
2-Year Total Return | -80.68% | |||
3-Year Total Return | -57.33% | |||
5-Year Total Return | -- | |||
52-Week High % Change | -72.39% | |||
52-Week Low % Change | 2.42% | |||
Price | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $4.60 | |||
52-Week Low Price | $1.24 | |||
52-Week Low Price (Date) | Mar 28, 2023 | |||
52-Week High Price (Date) | Apr 08, 2022 | |||
Valuation | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | $194.71M | |||
Enterprise Value | 2.92B | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.87 | |||
Earnings Per Share Growth | -1,435.49% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 0.09 | |||
Price/Book (Q) | 0.64 | |||
Enterprise Value/Revenue (TTM) | 1.32 | |||
Price | $1.31 | |||
Enterprise Value/EBITDA (TTM) | 6.64 | |||
Enterprise Value/EBIT | 14.61 | |||
Market Cap Category | Micro Cap | |||
Dividends and Shares | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 151.476M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 908 947 3120 | |||
Address | 400 Crossing Boulevard Bridgewater, NJ 08807 | |||
Website | amneal.com | |||
Country | United States | |||
Year Founded | 2002 | |||
Profitability | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | 9.04% | |||
Profit Margin | -5.87% | |||
Management Effectiveness | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | 3.23% | |||
Return on Equity | -- | |||
Income Statement | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | $2.21B | |||
Total Revenue (TTM) | $2.21B | |||
Revenue Per Share | $14.60 | |||
Gross Profit (TTM) | $791.46M | |||
EBITDA (TTM) | $440.21M | |||
EBIT (TTM) | $200.03M | |||
Net Income (TTM) | -$129.99M | |||
Net Income Avl. to Common (TTM) | -$129.99M | |||
Total Revenue Growth (Q YOY) | 13.57% | |||
Earnings Growth (Q YOY) | 71.37% | |||
EPS Diluted (TTM) | -$0.87 | |||
EPS Diluted Growth (Q YOY) | 27.63% | |||
Balance Sheet | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | $27.80M | |||
Cash Per Share (Q) | $0.18 | |||
Total Current Assets (Q) | $1.41B | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | $208.93M | |||
Current Ratio (Q) | 1.875 | |||
Book Value Per Share (Q) | $1.97 | |||
Total Assets (Q) | $3.80B | |||
Total Current Liabilities (Q) | $752.80M | |||
Total Debt (Q) | $2.85B | |||
Total Liabilities (Q) | $3.59B | |||
Total Common Equity (Q) | $298.42M | |||
Cash Flow | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -$174.31M | |||
Cash from Financing (TTM) | -$106.62M | |||
Net Change in Cash (TTM) | -$221.51M | |||
Levered Free Cash Flow (TTM) | $104.18M | |||
Cash from Operations (TTM) | $65.10M | |||